Ascent Biomedical Ventures

Peerbridge Health Inc. is a digital health company based in New York that specializes in remote monitoring of vital signs through its innovative wireless electrocardiogram (ECG) technology. The company has developed Peerbridge Cor, a multi-channel ECG monitor that provides physicians with real-time heart data and captures critical insights over a continuous seven-day period to aid in arrhythmia detection. In addition to Peerbridge Cor, the company offers Peerbridge CorHRV and Peerbridge Cor+, which monitor various vital signs including heart rate, respiratory rate, temperature, oxygen saturation, and heart rate variability (HRV). Peerbridge Health holds two patents related to medical-grade monitoring of vital signs, with additional patents pending, reflecting its commitment to enhancing healthcare delivery and patient outcomes through advanced technology. Founded in 2012, the company aims to improve the independence and precision of remote health monitoring for both medical and wellness applications.

Motus GI is a medical technology company that focuses on improving outcomes in endoscopy and enhancing patient experiences in the diagnosis and management of gastrointestinal conditions. Based in Fort Lauderdale, Florida, and with operations in Israel, the company has developed the Pure-Vu System, a medical device designed to assist in the cleaning of poorly prepared colons during colonoscopy procedures. This device aims to facilitate better visualization and improve the overall effectiveness of the colonoscopy, contributing to the early detection and prevention of colorectal cancer and other gastrointestinal diseases. The Pure-Vu System has received clearance from the U.S. Food and Drug Administration and is also CE marked for use in the European Economic Area.

eCaring Home Care Software offers Home Care Agencies a SaaS solution for scheduling, delivering, and billing home care services. We also offer mobile apps with Electronic Visit Verification (EVV) to support the delivery of home care services and secure communications for nurses and caregivers.

Covagen is a biopharmaceutical company focused on developing innovative therapies for inflammatory diseases and cancer. The company specializes in creating bispecific FynomAbs by genetically fusing its proprietary Fynomer binding proteins to antibodies. This unique approach allows for the design of therapeutics with novel mechanisms of action and improved efficacy. Covagen's lead product, COVA322, is aimed at treating inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis. The company was founded in 2007 as a spin-off from ETH Zurich and has established partnerships to enhance its drug development efforts, including a strategic collaboration with Mitsubishi Tanabe for the development of bispecific FynomAbs targeting specific disease-related pairs. A diverse group of investors supports Covagen’s initiatives, providing the necessary resources to advance its innovative therapeutic candidates.

Xlumena, Inc. specializes in developing image-guided therapeutic endoscopy products designed to enhance minimally invasive medical procedures. The company offers a range of innovative solutions, including the AXIOS Stent and Delivery System for treating pancreatic pseudocysts, and the NAVIX Access Device, which also addresses this condition. Additionally, Xlumena has created a self-expanding anchor stent for bile duct stenting, an integrated system for reliable pseudocyst drainage, and a method for repairing hiatal hernias from within the gastrointestinal lumen. Founded in 2007 and based in Mountain View, California, Xlumena operates as a subsidiary of Boston Scientific Corporation since April 2015.

Coferon is a biotechnology company that employs bioorthogonal linker chemistry to deliver therapeutic molecules in component parts that self assembles inside target cells. The Company is based at the Long Island High Tech Incubator on the campus of Stony Brook University in Stony Brook, New York.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Xlumena, Inc. specializes in developing image-guided therapeutic endoscopy products designed to enhance minimally invasive medical procedures. The company offers a range of innovative solutions, including the AXIOS Stent and Delivery System for treating pancreatic pseudocysts, and the NAVIX Access Device, which also addresses this condition. Additionally, Xlumena has created a self-expanding anchor stent for bile duct stenting, an integrated system for reliable pseudocyst drainage, and a method for repairing hiatal hernias from within the gastrointestinal lumen. Founded in 2007 and based in Mountain View, California, Xlumena operates as a subsidiary of Boston Scientific Corporation since April 2015.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

TargAnox is a biopharmaceutical company focused on developing therapeutic drugs aimed at treating oncology and metabolic-related illnesses. The company specializes in addressing stress-induced diseases by targeting oxidative stress, a biochemical condition linked to various health issues. TargAnox's innovative approach specifically focuses on oxidized cystine residues of key proteins implicated in human diseases. By providing advanced medicines that combat oxidative stress, TargAnox aims to enhance patient recovery and improve health outcomes for individuals suffering from these conditions.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Ouroboros, Inc. is a company based in San Diego, California, specializing in the manufacturing of spine products designed for the treatment of degenerated disc disease. The company focuses on developing innovative solutions to address the challenges associated with spinal disorders, aiming to improve patient outcomes through advanced medical technology.

InnerPulse, Inc. develops technology, devices, software protocols, and procedures to transform the treatment of cardiac arrhythmias. It offers invasive treatment that enables physicians to implant the life-saving Percutaneous Implantable Cardioverter Defibrillator within the patient's vascular system. InnerPulse, Inc. was formerly known as Interventional Rhythm Management, Inc.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Aryx Therapeutics is a biopharmaceutical company dedicated to developing innovative drug candidates that address safety concerns associated with established oral therapies for chronic diseases. Leveraging its expertise in retrometabolic drug design, Aryx aims to create safer alternatives to commercially successful medications. The company is committed to improving patient outcomes through its internally developed products, which are designed to mitigate known safety issues and enhance the effectiveness of existing treatments.

Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, dedicated to developing non-fusion motion preservation systems for treating degenerative diseases of the spine. Founded in 2003, the company offers two primary products: the M6-C artificial cervical disc and the M6-L artificial lumbar disc, both designed to replicate the anatomical and biomechanical characteristics of natural intervertebral discs. These innovations provide options for artificial disc replacement in the cervical and lumbar regions. Spinal Kinetics collaborates with spine surgeons to ensure that its products meet clinical needs and are sold through a network of distributors across various countries, including Australia, Germany, the United Kingdom, and the United Arab Emirates. The company operates as a subsidiary of Orthofix Medical Inc.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Entigo is a company that specializes in enterprise warranty chain management solutions, offering a suite of products designed to streamline warranty processes for businesses. Its flagship product, Entigo Warranty, allows organizations to manage warranty processing efficiently, while Entigo Catalyst provides strategic evaluations of existing warranty operations. The company also offers a range of consulting services, including project management, warranty process reengineering, systems integration, and training. These solutions automate key functions such as registration and claims handling, improving the speed of claims adjudication and problem resolution. By providing analytics and reporting capabilities, Entigo helps businesses enhance product quality and reduce warranty costs. The company's systems are designed to minimize errors and inefficiencies, ensuring seamless integration with warranty chain partners. Serving a diverse clientele, including Fortune 500 manufacturers in various industries such as automotive, aerospace, and electronics, Entigo aims to simplify warranty management and support operational excellence. Founded in 1995 and headquartered in Exton, Pennsylvania, Entigo is committed to delivering innovative solutions that meet the evolving needs of its customers.